Navigating Rare Liver Disease: Expert Insights and an Easy Egg and Black Bean Taco Recipe

When discussing liver health, conditions like fatty liver disease or hepatitis frequently dominate the conversation. However, there are ultra-rare, inherited disorders that require urgent clinical awareness due to their profound impact on newborns. Crigler-Najjar syndrome is an exceedingly rare condition (affecting roughly one in a million individuals) characterized by lifelong jaundice. In this exclusive feature, Jayanta Roy-Chowdhury, M.B.B.S., a professor of medicine at the Albert Einstein Cancer Center, breaks down the complex science behind this genetic disorder in plain language, explaining how mutations in a critical liver enzyme (UGT1A1) lead to a dangerous retention of bilirubin in the blood and tissues.

Roy-Chowdhury highlights a critical window for intervention, noting that while the condition should be suspected when severe newborn jaundice fails to normalize within two weeks, its sheer rarity means many physicians have never personally encountered it. If missed early on, extreme concentrations of bilirubin can enter the brain, resulting in irreversible neural damage known as kernicterus or bilirubin-induced neural damage (BIND).

Alongside this vital medical discussion, the feature highlights a nutritious, liver-healthy Egg and Black Bean Tacos recipe originally published by the American Liver Foundation (ALF). Packed with lean protein, fiber-rich black beans and served on corn tortillas, this simple, low-fat meal underscores the universal importance of supporting our body’s metabolic engine with wholesome, clean ingredients.

Egg and Black Bean Tacos

Ingredients:

• 4 large eggs
• 1 cup canned, low-sodium black beans, drained and rinsed
• 4 small corn tortillas
• 1/4 cup shredded, low-fat cheese (cheddar, Monterey Jack or Mexican blend)
• 1/4 cup salsa
• Optional: chopped cilantro, avocado slices or lime

Directions:

1. In a bowl, whisk the eggs.
2. Heat a nonstick skillet over medium heat and scramble the eggs until soft and cooked through.
3. Warm the corn tortillas until pliable.
4. Warm the canned black beans in a separate small pan or microwave.
5. Assemble the tacos: Layer scrambled eggs, warm black beans, a sprinkle of cheese and a spoonful of salsa onto each tortilla.
6. Add any optional toppings like cilantro, avocado or a squeeze of lime.

Crigler-Najjar syndrome is one of the rarest liver conditions that most people have never heard of. In plain language, what is it and what goes wrong in the body?

Jayanta Roy-Chowdhury, M.B.B.S.: Crigler-Najjar syndrome is a rare (about one in a million) inherited disorder characterized by lifelong jaundice, caused by retention of bilirubin in the blood and tissues. Bilirubin, a yellow pigment, is the breakdown product of heme, a red pigment derived from hemoglobin and a number of enzymes. The efficient excretion of bilirubin by the liver requires the action of a liver enzyme (UGT1A1) that converts this water-insoluble pigment to a water-soluble metabolite by conjugating it with a sugar molecule. A number of mutations in the gene that codes for UGT1A1 can result in abnormalities of this enzyme that abolish or severely reduce the activity of this enzyme. As a result, bilirubin accumulates in the blood plasma. At very high concentrations, bilirubin enters the brain, causing BIND, also known as kernicterus.

How is Crigler-Najjar typically diagnosed, and given how rare it is, how often does it get missed or mistaken for something else early on?

JRC: Crigler-Najjar syndrome should be suspected in the newborn period in babies in whom the high serum bilirubin levels seen within the first few days of life (neonatal jaundice) fails to normalize in one to two weeks and serum bilirubin remains fully or mostly unconjugated. Although this presentation should obviously raise the suspicion of Crigler-Najjar syndrome, because of the rarity of this disorder, most physicians do not have any prior experience with patients born with Crigler-Najjar syndrome. If the diagnosis is missed during the first few weeks of life, the infant may present with brain injury, characterized by cerebral palsy, abnormal movements and hearing loss.

There are two types of Crigler-Najjar syndrome. What is the difference between them, and why does that distinction matter so much for patients and families?

JRC: Crigler-Najjar syndrome type 1 (CN-1) is caused by complete or near-complete absence of UGT1A1 activity (bilirubin conjugation), resulting in very high levels of serum bilirubin, which is almost completely unconjugated. In the absence of prompt, vigorous and appropriate treatment, the child can develop permanent brain damage and can die during the first year of life. Occasionally, a patient may survive beyond puberty with intellectual and physical disability, eventually to succumb to the disease.

In Crigler-Najjar syndrome Type 2 (CN-2), also known as Arias syndrome, the UGT1A1 deficiency is severe, but not complete. These patients are also visibly jaundiced, but bilirubin levels are not as high as in CN-1. However, the serum bilirubin may spike to dangerous levels during intercurrent illnesses or fasting, potentially resulting in brain injury unless measures are taken to rapidly reduce the bilirubin levels. In contrast to CN-1, UGT1A1 activity can be increased by enzyme-inducing medicines, such as phenobarbital. This feature distinguishes CN-2 from CN-1.

What does day-to-day management look like for someone living with this condition, and what is the current standard of care?

JRC: CN-1 patients are treated by routine daily exposure to light (phototherapy), usually eight to 12 hours a day, which temporarily converts bilirubin to a water-soluble molecule that can be excreted in bile. This requires specially constructed light banks. When available, exposure of the skin to sunlight can be used to augment phototherapy by artificial light. Intercurrent illnesses or injuries requiring surgery can markedly increase serum bilirubin levels, requiring plasma exchange as a lifesaving emergency measure. Ultimately, the only cure for CN-1 patients is liver transplantation, which is usually performed around adolescence.

CN-2 patients can be generally managed with UGT1A1-inducing drugs, which can keep serum bilirubin at safe levels. During intercurrent illnesses, serum bilirubin levels may rise to dangerous levels, which may require intensive phototherapy or plasma exchange. Usually, CN-2 patients do not require liver transplantation.

What should patients and families understand about liver transplantation and what it involves?

JRC: Liver transplantation rapidly normalizes serum bilirubin levels in patients with CN-1. As normal livers have an excess capacity to conjugate and excrete bilirubin, transplantation of a single lobe is sufficient for this purpose. Therefore, liver from a living donor or from a deceased donor can be used for this purpose. Liver transplantation commits the recipient to long-term immunosuppressive therapy.

Where does research stand right now, and what gives you hope about where treatment for Crigler-Najjar is headed?

JRC: Novel approaches to the treatment of CN-1 are based on (a) transplantation of isolated liver cells or (b) gene therapy.

Liver cell transplantation, performed with cells isolated from a normal liver, is a much less invasive procedure than liver transplantation. But so far, the benefit of this procedure has been limited in duration and, like liver transplantation, commits the patient to long-term immunosuppressive therapy.

Gene therapy has the potential to replace liver transplantation for CN-1. However, currently used methods of gene transfer, namely using recombinant viruses, are not applicable to many patients because of the immune response against the viral carriers of the therapeutic genes, and limited duration of the therapeutic benefit. Future research should focus on RNA-based therapies, as well as gene editing, preferably using nonviral agents.